Saint Louis University School of Medicine is a private, Jesuit medical school. Part of Saint Louis University, the institution was established in 1836.

During the past decade, St. Louis Univ. School of Medicine AVEG conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 11 clinical trials were completed, i.e. on average, 78.6% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 6 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "St. Louis Univ. School of Medicine AVEG" #1 sponsor was "National Institute of Allergy and Infectious Diseases (NIAID)" with 39 trials, followed by "JANSSEN Alzheimer Immunotherapy Research & Development, LLC" with 3 trials sponsored, "NSABP Foundation Inc" with 3 trials sponsored, "Shire" with 3 trials sponsored and "Takeda" with 3 trials sponsored. Other sponsors include 19 different institutions and companies that sponsored additional 27 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "St. Louis Univ. School of Medicine AVEG" #1 collaborator was "National Cancer Institute (NCI)" with 4 trials as a collaborator, "Genentech, Inc." with 3 trials as a collaborator, "Immuno-US" with 3 trials as a collaborator, "Pfizer" with 3 trials as a collaborator and "Biocine" with 2 trials as a collaborator. Other collaborators include 21 different institutions and companies that were collaborators in the rest 29 trials.

According to Clinical.Site data, the most researched conditions in "St. Louis Univ. School of Medicine AVEG" are "HIV Infections" (40 trials), "Alzheimer's Disease" (3 trials), "Breast Cancer" (3 trials), "HIV Seronegativity" (3 trials) and "Coronary Artery Disease" (2 trials). Many other conditions were trialed in "St. Louis Univ. School of Medicine AVEG" in a lesser frequency.

Most popular intervention types in "St. Louis Univ. School of Medicine AVEG" are "Biological" (45 trials), "Drug" (26 trials), "Other" (4 trials), "Procedure" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "rgp120/HIV-1 SF-2" (10 trials), "ALVAC-HIV MN120TMG (vCP205)" (8 trials), "ALVAC-RG Rabies Glycoprotein (vCP65)" (7 trials), "Placebo" (7 trials) and "gp160 Vaccine (Immuno-AG)" (5 trials). Other intervention names were less common.

The vast majority of trials in "St. Louis Univ. School of Medicine AVEG" are 70 trials for "All" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "St. Louis Univ. School of Medicine AVEG". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 62 completed trials in St. Louis Univ. School of Medicine AVEG, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in St. Louis Univ. School of Medicine AVEG, 36 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 3 trials that are defined as “Not Applicable".